Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline
In This Article:
The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.
Oops, something went wrong
The pharma giant wants to refreshen its portfolio after some of its internal development programs disappointed in clinical trials.